Abstract
Chemotherapy-induced nausea and vomiting (emesis) can significantly affect a patient's quality of life, leading to poor adherence with further chemotherapy treatment. In addition, nausea and vomiting can result in other serious complications and deterioration of the patient's status. These guidelines explore the prevention, treatment, and management of various types of emesis experienced by cancer patients, such as breakthrough, radiation-induced, and anticipatory.
Original language | English (US) |
---|---|
Pages (from-to) | 12-33 |
Number of pages | 22 |
Journal | JNCCN Journal of the National Comprehensive Cancer Network |
Volume | 5 |
Issue number | 1 |
State | Published - Jan 1 2007 |
Externally published | Yes |
Keywords
- 5-HT3 receptor antagonists
- Anticipatory emesis
- Antiemesis
- Aprepitant
- Chemotherapy-induced emesis
- NCCN Clinical Practice Guidelines
- NK-1-receptor antagonists
- Nausea and vomiting
- Palonosetron
- Radiation-induced emesis
ASJC Scopus subject areas
- Oncology